Different effects of the serotonergic agonists buspirone and sumatriptan on the posterior pituitary hormonal responses to hypoglycemia in humans

Neuropeptides

Volumn 30, Issue 2, 1996, Pages 187-192

  Chiodera, P ^a   Volpi, R ^a   Capretti, L ^a   Caffarri, G ^a   Magotti, M G ^a   Coiro, V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; GLUCOSE; INSULIN; OXYTOCIN; SEROTONIN AGONIST; SUMATRIPTAN; VASOPRESSIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOGLYCEMIA; INSULIN TOLERANCE TEST; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OXYTOCIN BLOOD LEVEL; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL; SUBCUTANEOUS DRUG ADMINISTRATION; VASOPRESSIN BLOOD LEVEL;

EID: 0029904222     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(96)90086-4     Document Type: Article

References (22)

1. Baylis P H. Posterior pituitary function in health and disease. Clin Endocrinol Metab 1983; 12: 747-770.
2. Fisher BM, Baylis PH, Frier BM Plasma oxytocin, arginine vasopressin and atrial natriuretic peptide responses to insulin-induced hypoglycaemia in man. Clin Endocrinol 1987; 26: 179-185.
3. Chiodera P, Volpi R, Capretti L et al. Hypoglycemia-induced arginine-vasopressin and oxytocin release is mediated by glucoreceptors located inside the blood-brain-barrier. Neuroendocrinology 1992; 55: 655-659.
4. Oomura Y. Glucose as a regulator of neuronal activity. Adv Metab Disord 1983; 10: 32-65.
5. Caraty A, Grino M, Locatelli A et al. Insulin-induced hypoglycemia stimulates corticotropin releasing factor and arginine vasopressin secretion into hypophysial portal blood of conscious unrestrained rams. J Clin Invest 1990; 85: 1716-1721.
6. De Goeij DCE, Binnekade R, Tilderes FJH. Chronic stress enhanced vasopressin but not corticotropin-releasing factor secretion during hypoglycemia. Am J Physiol 1992; 263: E394-E399.
7. Coiro V, Capretti L, Speroni G et al. Increase by naloxone of arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in obese men. J Endocrinol Invest 1990; 13: 757-763.
8. Bivens CH, Lebovitz ME, Feldman JM. Inhibition of hypoglycemia-induced growth hormone secretion by the serotonin antagonist cyproeptadine and methysergide. N Engl J Med 1973; 289: 236-239.
9. Plonk JU, Bivens CU, Feldman JM. Inhibition of hypoglycaemia induced cortisol secretion by the serotonin antagonist cyproeptadine. J Clin Endocrinol Metab 1974; 38: 836-840.
10. Masala A, Delitala G, Devilla L, Alagna S, Rovasio PP. Enhancement of insulin induced prolactin secretion by fluoxetine in man. J Clin Endocrinol Metab 1979; 49: 350-352.
11. Prescott RWG, Kendall-Taylor P, Weightman DR, Watson MJ, Ratcliffe WA. The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycaemia in normal subjects. Clin Endocrinol 1984; 20: 137-142.
12. Gibbs DM, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res 1983; 280: 176-179.
13. Van der Kar LD. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Ann Rev Pharmacol Toxicol 1991; 31: 187-320.
14. Bagdy G, Sved AF, Murphy DL, Szemered K. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur J Pharmacol 1992; 210: 285-289.
15. Li Q, Levy AD, Cabrera TM, Brownfield MS, Battaglia G, Van der Kar LD. Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist 8-OH-DPAT in male rats. Brain Res 1993; 630: 148-156.
16. Pergola PE, Sved AF, Voggt JL, Alper RH. Effect of serotonin on vasopressin release: a comparison to corticosterone, prolactin and renin. Neuroendocrinology 1993; 57: 550-558.
17. Thompson CJ, Jones IR, Walker M, Baylis PH, Kendall-Taylor P. The effects of the specific serotonin antagonist ICI 169, 369 on the pituitary hormone response to insulin-induced hypoglycaemia in humans. Clin Endocrinol 1992; 36: 235-240.
18. Schoeffter P, Hoyer D. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 135-138.
19. Moser PC, Tricklebank MD, Middlemiss DN, Mir AK, Hibert MF, Fozard JM. Characterization of MDL 73005 FF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam. Br J Pharmacol 1990; 99: 343-349.
20. Coiro V, Passeri, d'Amato L et al. Oxytocin responses to insulin-induced hypoglycemia in obese subjects before and after weight loss. J Endocrinol Invest 1988; 11: 125-128.
21. Chiodera P, Louis F, Legros JJ. Simultaneous radioimmunoassays for plasma arginine-vasopressin and oxytocin using DEAE sephadex A-25 extraction. J Endocrinol Invest 1984; 7: 287-293.
22. Moeller FG, Steinberg JL, Fulton M, Kramer G, Petty F. A preliminary neuroendocrine study with buspirone in major depression. Neuropsychopharmacology 1994; 10: 75-83.